Study of PM060184 in Patients With Advanced Solid Tumors
30. oktober 2015 oppdatert av: PharmaMar
Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM060184 Administered Intravenously to Patients With Advanced Solid Tumors
The purpose of the study is to determine the maximum tolerated dose and the recommended dose and to evaluate the safety and tolerability of PM060184.
Studieoversikt
Detaljert beskrivelse
This trial intends to determine the maximum tolerated dose and the recommended dose, to evaluate the safety and tolerability, to determine the pharmacokinetics and to evaluate the antitumor activity of PM060184 in patients with advanced solid tumors.
Studietype
Intervensjonell
Registrering (Faktiske)
60
Fase
- Fase 1
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Texas
-
San Antonio, Texas, Forente stater, 78229
- START- South Texas Accelerated Research Therapeutics, LLC
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion criteria
- Voluntary signed and dated written informed consent.
- Patients with advanced solid tumors refractory to Standard therapy.
- Age >/= 18 years.
- Recovery from drug-related adverse events (AEs) of previous treatments, excluding alopecia.
- Normal laboratory values within seven days prior to treatment administration.
- Women of childbearing potential must have a negative serum pregnancy test before study entry. Both men and women must agree to use a medically acceptable method of contraception throughout the treatment period and for three months after discontinuation of treatment.
Exclusion criteria
- Pregnant or lactating women.
- Less than three weeks from radiation therapy or last dose of hormonal therapy, biological therapy or chemotherapy
- Prior treatment with any investigational product less than 30 days prior to the first.
- Central Nervous System metastases
Other relevant diseases or adverse clinical conditions:
- Increased cardiac risk:
- Presence of significant neurological or psychiatric disorders
- Neuropathy
- Active infection requiring treatment.
- Liver disease (e.g., cirrhosis, hepatitis).
- Immunocompromised patients.
- Any other major illness.
- Limitation of the patient's ability to comply with the treatment.
- Known hypersensitivity to any of the components of the drug product.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: PM060184
|
PM060184 administered intravenously (i.v.) over 10 minutes at a starting dose of 4 mg/m2/day on three consecutive days q2w (on Days 1-3 and 15-17) every 28 days.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
MTD (maximum tolerated dose) and RD (recommended dose) of PM060184.
Tidsramme: From treatment onset to end of treatment
|
To determine the maximum tolerated dose (MTD) and the recommended dose (RD) of PM060184 administered on Days 1 and 8 of a 21-day cycle intravenously (i.v.) over 10 minutes to patients with advanced solid tumors.
|
From treatment onset to end of treatment
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
To determine the pharmacokinetics of this drug in patients who have advanced solid tumors.
Tidsramme: Blood samples will be collected up to 48 hours after the first infusion. At the RD, 24-h urine collection samples and 15 additional blood samples up to 48 hours after the second infusion of the first cycle.
|
The complete plasma concentration-time profiles of PM06184 will be analyzed by standard non-compartmental methods.The percent of PM060184 total dose excreted unchanged into the urine over the collection interval will be calculated from the urine samples.
|
Blood samples will be collected up to 48 hours after the first infusion. At the RD, 24-h urine collection samples and 15 additional blood samples up to 48 hours after the second infusion of the first cycle.
|
|
Antitumor activity
Tidsramme: Every six weeks while on treatment. Patients who discontinued treatment without disease progression will be followed every three months until disease progression, other antitumor therapy, death or until the end-of-study date, whichever occurs first.
|
Antitumor activity will be measured according to the RECIST (Response Evaluation Criteria In Solid Tumors) version 1.1 or by evaluation of tumor markers
|
Every six weeks while on treatment. Patients who discontinued treatment without disease progression will be followed every three months until disease progression, other antitumor therapy, death or until the end-of-study date, whichever occurs first.
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Etterforskere
- Hovedetterforsker: Kyriakos Papadopoulos, MD, START- South Texas Accelerated Research Therapeutics, LLC
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. januar 2011
Primær fullføring (Faktiske)
1. august 2015
Studiet fullført (Faktiske)
1. august 2015
Datoer for studieregistrering
Først innsendt
9. februar 2011
Først innsendt som oppfylte QC-kriteriene
17. februar 2011
Først lagt ut (Anslag)
18. februar 2011
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
1. november 2015
Siste oppdatering sendt inn som oppfylte QC-kriteriene
30. oktober 2015
Sist bekreftet
1. oktober 2015
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- PM60184-A-002-10
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .